Literature DB >> 2477002

A major autoepitope is present on the amino terminus of a human SS-A/Ro polypeptide.

T S Lieu1, M M Newkirk, F C Arnett, L A Lee, J S Deng, J D Capra, R D Sontheimer.   

Abstract

A human SS-A/Ro antigen is present on the polypeptide component of a particle composed of hyRNA and a 60 kD protein. We have now purified the Wil-2 cell 60 kilo dalton (kD) SS-A/Ro protein and determined its amino-terminal amino acid sequence. A synthetic peptide corresponding to residues 7 to 24 of this sequence (RoSP7-24) exhibited enzyme-linked immunosorbent assay (ELISA) binding activity with immunodiffusion-defined, monospecific anti-SS-A/Ro sera. In addition, ELISA binding of monospecific anti-SS-A/Ro sera to native SS-A/Ro antigen was partially inhibited (35%) by KLH-RoSP7-24. Sera from patients known to frequently produce precipitating anti-SS-A/Ro antibody (subacute cutaneous lupus erythematosus [SCLE], 56 patients; Sjögren's syndrome [SS], 41 patients; mothers of infants with neonatal LE [NLE], 10 individuals; infants with congenital heart block [CHB], 5 patients) were tested for reactivity to RoSP7-24 in ELISA. Overall, 38% of SCLE sera, 36% of SS sera, 50% of maternal NLE sera and 20% of CHB infant sera had anti-RoSP7-24 binding levels greater than 2 standard deviations above the mean of that of normal individuals. Of the sera which had anti-SS-A/Ro detected by double immunodiffusion and/or counterimmunoelectrophoresis, 68% of SCLE patients, 71% of SS patients, 55% of NLE mothers and 20% of CHB infants had significantly elevated RoSP7-24 ELISA binding levels. These findings strongly suggest that a major autoepitope of native human SS-A/Ro resides on the amino terminal portion of the Wil-2 SS-A/Ro 60 kD polypeptide.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2477002     DOI: 10.1016/0896-8411(89)90165-0

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  7 in total

1.  Fine specificity of autoantibodies to calreticulin: epitope mapping and characterization.

Authors:  P Eggleton; F J Ward; S Johnson; M A Khamashta; G R Hughes; V A Hajela; M Michalak; E F Corbett; N A Staines; K B Reid
Journal:  Clin Exp Immunol       Date:  2000-05       Impact factor: 4.330

2.  Molecular cloning, expression, and chromosome 19 localization of a human Ro/SS-A autoantigen.

Authors:  D P McCauliffe; F A Lux; T S Lieu; I Sanz; J Hanke; M M Newkirk; L L Bachinski; Y Itoh; M J Siciliano; M Reichlin
Journal:  J Clin Invest       Date:  1990-05       Impact factor: 14.808

Review 3.  Neonatal lupus: clinical features, therapy, and pathogenesis.

Authors:  L A Lee
Journal:  Curr Rheumatol Rep       Date:  2001-10       Impact factor: 4.592

4.  Serological cross-reactivity between a human Ro/SS-A autoantigen (calreticulin) and the lambda Ral-1 antigen of Onchocerca volvulus.

Authors:  F A Lux; D P McCauliffe; D W Büttner; R Lucius; J D Capra; R D Sontheimer; T S Lieu
Journal:  J Clin Invest       Date:  1992-06       Impact factor: 14.808

Review 5.  Calreticulin: not just another calcium-binding protein.

Authors:  P D Nash; M Opas; M Michalak
Journal:  Mol Cell Biochem       Date:  1994-06-15       Impact factor: 3.396

6.  Cellular mechanism of the conduction abnormalities induced by serum from anti-Ro/SSA-positive patients in rabbit hearts.

Authors:  S Garcia; J H Nascimento; E Bonfa; R Levy; S F Oliveira; A V Tavares; A C de Carvalho
Journal:  J Clin Invest       Date:  1994-02       Impact factor: 14.808

Review 7.  Neonatal lupus: clinical features and management.

Authors:  Lela A Lee
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.